新型抗风湿病药物降低肾移植受者群体反应性抗体水平的回顾性研究

Retrospective study of a novel anti-rheumatic drugs to reduce the panel reactive antibody of kidney transplant recipients

目的:观察新型抗风湿病药物艾拉莫德降低肾移植受者群体反应性抗体(PRA)水平的有效性和安全性。方法:回顾性分析35例因PRA阳性服用艾拉莫德的肾移植受者临床资料,观察治疗前后的PRA水平变化以及用药不良反应情况。结果:35例中4例因肺部感染停药未达随访时间,2例观察期间自行停药,3例失访,共纳入26例受者。服用艾拉莫德至9个月时复查PRA,207个位点中有71.5%呈下降趋势,其中107个Ⅰ类位点中有69.9%、41个Ⅱ类位点中有75.9%呈下降趋势,治疗前后肾功能及免疫指标变化差异无统计学意义。血常规、肝功能、血脂、空腹血糖等指标变化无统计学意义。无其他不良反应。结论:艾拉莫德可有效降低肾移植受者PRA水平,不良反应少,安全性高。

Objective To observe the efficacy and safety of Iguratimod in reducing the level of panel reactive antibodies in renal transplant recipients.Methods The clinical data of 35 patients with PRA-positive renal transplant recipients were retrospectively analyzed.All recipients were treated with Iguratimod for PRA-positive.The changes in PRA levels before and after treatment and the adverse events were observed.Results Of the 35 recipients,4 of them were discontinued due to pulmonary infection,and 2 patients were discontinued during the observation period.3 patients were lost to follow-up.A total of 26 recipients were included.When Iguratimod was taken to 9 months,the PRA was reviewed.71.5%of the 207 sites showed a downward trend,69.9%of the 107 class I sites and 75.9%of the 41 class II site showed a downward trend,and there was no difference in renal function before and after treatment.There were no significant changes in blood routine,liver function,blood lipids,and blood glucose.There were no other adverse events.Conclusions Iguratimod can effectively reduce the level of PRA in renal transplant recipients with less adverse events.